Skip to main content
. 2023 May 10;45(4):922–928. doi: 10.1007/s11096-023-01587-9

Table 3.

Age, number of drugs, number of uterotonics, and the reported outcomes, stratified by the two drugs and the haemodynamic effects of interest

Hypotension Hypertension Tachycardia Bradycardia
O C O C O C O C
Total (%)* 223 (2.0) 19 (5.1) 80 (0.7) 9 (2.4) 231 (2.1) 21 (5.6) 91 (0.8) 6 (1.6)
Outcome (%)
Death 4 (1.8) 0 1 (1.3) 0 6 (2.6) 0 2 (2.2) 0
Not recovered/recovered with a sequela 2 (0.9) 1 (5.3) 5 (6.3) 0 2 (0.9) 1 (4.8) 3 (3.3) 0
Recovering 11 (4.9) 2 (10.5) 11 (13.8) 2 (22.2) 42 (18.2) 3 (14.3) 8 (8.8) 0
Fully recovered 150 (67.3) 14 (73.7) 47 (58.8) 7 (77.8) 143 (61.9) 11 (52.4) 59 (64.8) 5 (83.3)
Unknown 31 (13.9) 2 (10.5) 11 (13.8) 0 21 (9.1) 1 (4.8) 15 (16.5) 0
Not reported 25 (11.2) 0 5 (6.3) 0 17 (7.4) 5 (23.8) 4 (4.4) 1 (16.7)
Age [y], Mean (SD) 30.0 (6.2) 34.8 (14.8) 30.0 (6.8) 34.2 (5.8) 29.5 (8.2) 30.6 (3.6) 29.9 (8.6) 31.8 (3.3)
Other uterotonics present (%) 12 (5.4) 2 (10.5) 18 (22.5) 2 (22.2) 15 (6.5) 2 (9.5) 3 (3.3) 0
Adrenergics present (%) 12 (5.4) 2 (10.5) 5 (6.3) 0 9 (3.9) 2 (9.5) 0 1 (16.7)

O = Oxytocin; C = Carbetocin; Uterotonics included: “Methylergometrine”, “Ergot alkaloids”, “Ergometrine”, “Dinoprostone”, “Gemeprost”, “Carboprost”, “Sulprostone”, “Misoprostol”. Adrenergics included: “Etilefrine”, “Isoprenaline”, “Norepinephrine”, “Dopamine”, “Norfenefrine”, “Phenylephrine”, “Dobutamine”, “Oxedrine”, “Metaraminol”, “Methoxamine”, “Mephentermine”, “Dimetofrine”, “Prenalterol”, “Dopexamine”, ”Gepefrine”, “Ibopamine”, “Midodrine”, “Octopamine”, “Fenoldopam”, “Cafedrine”, “Arbutamine”, “Theodrenaline”, “Epinephrine”, “Amezinium Metilsulfate”, “Ephedrine”, “Droxidopa”

*The percentage refers to all reports of the respective drug

The percentage refers to the respective outcome and the respective drug